AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02020330
Drug: Artemether-lumefantrine 5 days
RxNorm normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
Trial: NCT01395628
Drug: in vitro sensitivity-directed chemotherapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02624908
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
Trial: NCT02849951
Drug: LT-02
RxNorm normalized name: LT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
Trial: NCT01103843
Drug: Maintenance Dose Arm
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
Trial: NCT00380497
Drug: PEG-Lyte®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00380497
Drug: Pico-Salax®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01366209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo equivalent given as 3 divided doses 3 times per day.
Trial: NCT01397578
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating intravenous infusion
Trial: NCT01753791
Drug: 80 mg PF-06473871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of PF-06473871 or placebo
Trial: NCT01753791
Drug: 160 mg PF-06473871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of PF-06473871 or placebo
Trial: NCT01753791
Drug: 320 mg PF-06473871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg of PF-06473871 or placebo
Trial: NCT00809705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc once weekly for 12 weeks
Trial: NCT03073798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mcg of placebo is used
Trial: NCT03066544
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
Trial: NCT01053221
Drug: Mycophenolic Acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
Trial: NCT01053221
Drug: Standard of Care: CNI and MPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
Trial: NCT00841659
Drug: Paxil®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Film-Coated Tablet
Trial: NCT06001463
Drug: CSMed Dressing
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of the irradiated area was covered with CSMed® and the other half was under routine treatment. An irradiated area of 11cm\*14cm with best fit or easy accessibility was chosen for CSMed® dressing application. The area without dressing was treated with routine skin care in each patient.
Trial: NCT02385708
Drug: 2% Chlorohexidine Gluconate Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
Trial: NCT02385708
Drug: 2% Chlorohexidine Gluconate Chin to Toe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
Trial: NCT04171115
Drug: G03-52-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G03-52-01 administered intramuscularly
Trial: NCT04171115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intramuscularly
Trial: NCT04464889
Drug: MDG1021 dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 patients to receive dose1: target dose of 0.3x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
Trial: NCT04464889
Drug: MDG1021 dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 patients to receive dose 2: target dose of 1x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
Trial: NCT04464889
Drug: MDG1021 dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 patients to receive dose 3: target dose of 3x10\^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
Trial: NCT04464889
Drug: MDG1021 optimal dose
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 patients to receive the selected optimal dose
Trial: NCT00538109
Drug: Glivec®/Gleevec®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT00438984
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02442687
Drug: JKB-121: 5 mg twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02442687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00420927
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
Trial: NCT00002744
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002744
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002744
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002744
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002744
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00382460
Drug: PRAVASTATIN SODIUM
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01947205
Drug: dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02419508
Drug: Brinz/brim vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo for masking purposes
Trial: NCT02280278
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02447848
Drug: sufentanil sublingual 30 mcg tablet
RxNorm normalized name: sufentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001698
Drug: Ketorolac Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00834873
Drug: COREG® 25 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 25 mg
Trial: NCT00354835
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01769898
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline 0.1 Q12H
Trial: NCT01769898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for theophylline 0.1 Q12H
Trial: NCT01968551
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Trial: NCT01968551
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg tablet administered orally once daily
Trial: NCT01968551
Drug: Baseline DRV- containing ARV regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take their baseline DRV- containing ARV regimen as prescribed.
Trial: NCT03982537
Drug: N-Acetyl-L-Cysteine dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
Trial: NCT02055547
Drug: MK-8521 150μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 150μg SC injection in a treatment period (Part 1, Panel B)
Trial: NCT03938389
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
Trial: NCT02055547
Drug: MK-8521 50/72μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)
Trial: NCT02055547
Drug: MK-8521 72/125μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)
Trial: NCT02055547
Drug: MK-8521 100/150μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)
Trial: NCT02055547
Drug: MK-8521 125/150μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)
Trial: NCT02055547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
Trial: NCT04260373
Drug: [14C]SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single dose of orally \[14C\]SHR4640 on Day 1.
Trial: NCT00573313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
Trial: NCT04143607
Drug: ASK120067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT04143607
Drug: Placebo ASK120067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT03031795
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT03031795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT04015024
Drug: SKLB1028 150mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg oral administration twice a day
Trial: NCT04015024
Drug: SKLB1028 200mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg oral administration twice a day
Trial: NCT04015024
Drug: SKLB1028 300mg qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg oral administration once a day
Trial: NCT03232021
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule administered 1 hour prior to the surgical operation
Trial: NCT03856164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
Trial: NCT01220622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo 30mg tid for 6 months
Trial: NCT01600963
Drug: Arm A Double-blind Phase: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
Trial: NCT01600963
Drug: Arm B Double-blind Phase: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
Trial: NCT01600963
Drug: Treatment Failure During Double-blind Phase: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
Trial: NCT01600963
Drug: Treatment Failure During Follow-up Phase: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
Trial: NCT00087529
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00518986
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01301430
Drug: H-1PV
RxNorm normalized name: Synovex H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
Trial: NCT02660502
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of a single dose of Humalog® at the dose of 0.2 U/kg
Trial: NCT01972230
Drug: Diprivan + Remifentanil TCI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06626971
Drug: ARA290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg subcutaneous injections of ARA290 over an 84 day period
Trial: NCT01430442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant placebo-matching capsules
Trial: NCT03718143
Drug: AZD1775 only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 days 1-5 \& 8-12
Trial: NCT00699517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. infusion followed by administration of cisplatin
Trial: NCT00767377
Drug: EOF5
RxNorm normalized name: Ethinyl Estradiol and Norgestimate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
Trial: NCT00494897
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00494897
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00919113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The identical buffer used in Uracyst for the same administration
Trial: NCT00543205
Drug: Genasense® (G3139, oblimersen sodium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genasense 7 mg/kg/day for 5 days
Trial: NCT00494897
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00142883
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill compared to pregabalin
Trial: NCT04309968
Drug: Drug: SYHA1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SYHA1801 administered orally
Trial: NCT02764515
Drug: Kunxian Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
Trial: NCT02764515
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
Trial: NCT01285713
Drug: 5% Dextrose (D5) in Normal Saline (NS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
Trial: NCT00911053
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
Trial: NCT01283503
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02832960
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Trial: NCT03636061
Drug: OC-01 (varenicline) nasal spray
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline) nasal spray
Trial: NCT03636061
Drug: Placebo (vehicle) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03217331
Drug: CRD-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg CRD-102 capsules administered twice daily orally for 14 days.
Trial: NCT01602692
Drug: Tumescent solution with dilute lidocaine and epinephrine
RxNorm normalized name: epinephrine / lidocaine Injectable Solution [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
Trial: NCT01602692
Drug: Tumescent Solution with dilute epinephrine
RxNorm normalized name: Sensorcaine with Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tumescent Solution containing dilute epinephrine (1:1,000,000) only
Trial: NCT01343498
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
Trial: NCT02549716
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
Trial: NCT00353262
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg/m2 po bid (cycles 1, 2 and 3)
Trial: NCT02549716
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
Trial: NCT00688753
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03591471
Drug: Sulfotanshinone Sodium Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
Trial: NCT03591471
Drug: Chinese herbs based on syndrome differentiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome.
Trial: NCT02549716
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
Trial: NCT02549716
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
Trial: NCT00003414
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes